Organon Enters into Agreement to License MIUDELLA®, Sebela Pharmaceuticals’ Hormone-Free Intrauterine Device

MIUDELLA® is a strategic addition to Organon’s portfolio, strengthening its long‑term commitment to advancing women’s health JERSEY CITY, N.J., February 23, 2026 — Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, announced today that it has entered into an agreement to exclusively… Read more »

DFW Completes Sale of Sev1Tech to ERT, a Macquarie Capital-backed company

DFW Completes Sale of Sev1Tech to ERT, a Macquarie Capital-backed company DFW Capital Partners (“DFW”) is pleased to announce that it has completed the sale of its portfolio company, Sev1Tech (“Sev1Tech”, or the “Company”) to ERT, a Macquarie Capital-backed company. Sev1Tech is a provider of IT modernization, cloud, cybersecurity, engineering, training and program support services… Read more »

DFW Capital Partners Promotes Patrick Fairfield to Principal

DFW Capital Partners announced today that Patrick Fairfield has been promoted to Principal. Fairfield joined DFW in 2017 as an Associate and has advanced through roles of increasing responsibility, earning his promotion through strong performance and leadership across the firm’s investment activities. In his new role, Fairfield will continue to play a key part in… Read more »

B&A Acquires Celestar, Expanding Intelligence Capabilities Across Defense and Intelligence Markets

Acquisition Broadens B&A’s Intelligence Capabilities and Strengthens its Position as a Growing National Security Partner   McLean, Va., January 13, 2026 – B&A, a leading information technology systems integrator serving the federal government, today announced it has acquired Celestar Corporation, a global, multi-disciplinary intelligence services and solutions provider. Celestar provides specialized intelligence and analytic support to… Read more »

Sebela Pharmaceuticals® Announces Submission of New Drug Application to FDA for Tegoprazan for the Treatment of Gastroesophageal Reflux Disease

Key Highlights: Sebela Pharmaceuticals® submitted its New Drug Application (NDA) for tegoprazan on January 9, 2026.  The NDA seeks approval for three indications: Non-Erosive Reflux Disease (NERD), Erosive Esophagitis (EE) Healing, and EE Maintenance Once approved, tegoprazan will be the first Potassium-Competitive Acid Blocker (P-CAB) to demonstrate superiority in EE healing across all severity grades (LA… Read more »

Azurity Pharmaceuticals and Sebela Pharmaceuticals Announce the Sale of Sebela’s Bowel Prep Franchise to Azurity

Azurity Pharmaceuticals and Sebela Pharmaceuticals Announce the Sale of Sebela’s Bowel Prep Franchise to Azurity This Strategic Transaction Expands Azurity’s Existing Gastrointestinal Portfolio Woburn, MA – November 17, 2025 – Azurity Pharmaceuticals and Sebela Pharmaceuticals announced today Azurity’s successful acquisition of Sebela’s Bowel Prep Franchise, including two leading bowel preparation therapies for colonoscopies. Ronald Scarboro,… Read more »

Phase 3 Data Publication in Contraception

MIUDELLA® Hormone-Free Copper Intrauterine System (IUS) Phase 3 Data Publication in Contraception Honored with Daniel Mishell, Jr., MD Outstanding Article Award at Society of Family Planning Annual Meeting Study Investigators David K. Turok, MD, MPH and Mitchell Creinin, MD Honored at the Society for Family Planning Annual Meeting In Pittsburgh ROSWELL, GA, October 27, 2025… Read more »

North American Rail Solutions Combines with ZA Railroad Services

Fort Worth, Texas September 4, 2025 North American Rail Solutions, a portfolio company of DFW Capital Partners, has completed a business combination with ZA Railroad Services and its affiliated companies (collectively “ZA”), creating the leading North American provider of specialized railway infrastructure inspection, maintenance, repair and construction services to industrial, short-line, Class 1 and select… Read more »

Singlepoint Launches Integrated Care Model for Inflammatory Disease

CHICAGO, Ill., July 30, 2025 /PRNewswire/ — Singlepoint Healthcare (Singlepoint), today announced its official launch as a new healthcare organization focused on providing integrated, patient-centered care for individuals living with complex inflammatory diseases, combining best-in-class infusion services with holistic disease management. Singlepoint is building a multi-specialty network that brings neurology, rheumatology and immunology together with key ancillary services… Read more »

Herspiegel Acquires Decisive Consulting, Building Global Presence

Herspiegel, a portfolio company of DFW Capital Partners, and a leader in pharmaceutical commercialization consulting services, today announced the acquisition of U.K.-based Decisive Consulting, following the company’s acquisition of leading U.K.-based HEOR and market access firm FIECON in April 2025.  This strategic expansion unites Decisive’s global market access focused “Rebel Thinking” with Herspiegel’s world-class commercialization… Read more »